To report on the Objective: Sanka et al (2012) Inclusion/exclusion criteria Confirming a diagnosis NHMRC level of evidence: IV outcomes of performing magnetic Inclusion: confirmed or suspected 8 normal MRE patients discharged – resonance enteroclysis in the CD or ulcerative colitis England, single 1 normal MRE no changes Quality: Q3 POOR – diagnosis and management of centre Exclusion: not stated Comparison: C1: other comparison (no comparison) children with inflammatory bowel Changes in management Applicability: P2 limited (unclear) disease. N=34 Patient characteristics: 2 patients commenced azathioprine Age/Gender: 45% male, mean age 7 patients commenced infliximab, 4 had QUADAS Study design: 15.3 years, CD confirmed in 19 ileo-caecal resection, adalimumab in 3 Prospective: no Retrospective patients patients, 1 patient referred to Consecutive: unclear/yes psychological support, Explicit selection criteria: yes 09/2008-11/2010 Timing: Length of time with 6 patients for complx, 5 normal and Reference standard: n/a disease: not stated continued current management, 1 Test interval in days/weeks: n/a Index test: MR enteroclysis. significant complx, Prior tests: Not stated Previous afternoon upper Tests and ref std well described/reproducible: yes Other one underwent surgery, one – Clinical characteristics: endoscopy to place naso-jejunal Tests assessed and independent of ref std: n/a patient commenced methotrexate Symptoms not stated tube. Ref std assessed and blinded to other tests: n/a Routine clinical data available: yes Limitations in use of MR enterocylsis Comparator test: n/a Uninterpretable/intermed results reported: no 2 patients did not complete MR enterogclysis (1 extreme discomfort from withdrawals explained: yes Timing interval: n/a stricture, 1 claustrophobia) Sufficient data for 2x2 table: n/a Reference test: n/a Relevant population: yes Applicable comparator: n/a Test interpretation: MR Applicable intervention: yes enteroclysis evaluated by one radiologist with expertise in gastrointestinal imaging.
Sanka et al (2012) England, single centre N=34 Objective: To report on the outcomes of performing magnetic resonance enteroclysis in the diagnosis and management of children with inflammatory bowel disease. Study design: Retrospective Timing: 09/2008-11/2010 Index test: MR enteroclysis. Previous afternoon upper endoscopy to place naso-jejunal tube. Comparator test: n/a Timing interval: n/a Reference test: n/a Test interpretation: MR enteroclysis evaluated by one radiologist with expertise in gastrointestinal imaging. Inclusion/exclusion criteria Inclusion: confirmed or suspected CD or ulcerative colitis Exclusion: not stated Patient characteristics: Age/Gender: 45% male, mean age 15.3 years, CD confirmed in 19 patients Length of time with disease: not stated Prior tests: Not stated Clinical characteristics: Symptoms not stated Confirming a diagnosis 8 normal MRE – patients discharged 1 normal MRE – no changes Changes in management 2 patients commenced azathioprine 7 patients commenced infliximab, 4 had ileo-caecal resection, adalimumab in 3 patients, 1 patient referred to psychological support, 6 patients for complx, 5 normal and continued current management, 1 significant complx, Other – one underwent surgery, one patient commenced methotrexate Limitations in use of MR enterocylsis 2 patients did not complete MR enterogclysis (1 extreme discomfort from stricture, 1 claustrophobia) NHMRC level of evidence: IV Quality: Q3 POOR Comparison: C1: other comparison (no comparison) Applicability: P2 limited (unclear) QUADAS Prospective: no Consecutive: unclear/yes Explicit selection criteria: yes Reference standard: n/a Test interval in days/weeks: n/a Tests and ref std well described/reproducible: yes Tests assessed and independent of ref std: n/a Ref std assessed and blinded to other tests: n/a Routine clinical data available: yes Uninterpretable/intermed results reported: no withdrawals explained: yes Sufficient data for 2x2 table: n/a Relevant population: yes Applicable comparator: n/a Applicable intervention: yes
1190_MRICrohnsDisease_AttA_FinalCAreport_14Jan2014%20accessible.docx